WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics, a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, today announced that results of a Phase 1 study of LYR-210, the company’s drug product in development for chronic rhinosinusitis (CRS), have been selected for an oral presentation at the 64th Annual Meeting of the American Rhinologic Society (ARS), taking place October 5-6 in Atlanta, Ga.
The oral presentation will be given by Richard Douglas, MD, the lead investigator in the LYR-210 clinical study, and will describe clinical results from the Phase 1 study of LYR-210 in chronic rhinosinusitis (CRS). Details of the presentation on LYR-210 are as follows:
|
Title: |
Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis | |||
|
Presenter: |
Richard Douglas, MD, FRACS, FRACP, MRCP, Professor of Surgery at The University of Auckland, New Zealand, and Consultant Surgeon at Auckland City Hospital |
|||
|
Abstract #: |
2530 | |||
|
Date and Time: |
Friday, October 5, 2018 3:40 – 3:50 pm ET | |||
The 2018 annual meeting of the ARS is being held in conjunction with the annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), also being held in Atlanta.
About LYR-210
LYR-210 has the potential to be the first approved drug product for chronic rhinosinusitis (CRS) and is the only product announced in development to offer six months of drug therapy with a single administration. Utilizing Lyra’s proprietary transmucosal therapeutic system, LYR-210 is engineered to deliver a custom long-acting formulation of an approved steroid, mometasone furoate, deep into the sinonasal tissues that are not accessible with conventional therapeutic approaches. LYR-210 is biodegradable and is designed to be administered by a physician in a routine office visit.
About Lyra Therapeutics
Lyra Therapeutics is a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, offering an alternative to conventional treatments or surgeries. The company’s lead drug candidate, LYR-201, offers a novel approach for directing medicine deep into sinonasal tissues for releasing anti-inflammatory therapy for up to six months. With proprietary expertise in drug development and materials science, Lyra is applying its transmucosal therapeutic system – comprised of drug administered through a polymeric matrix – with the goal of enabling therapeutic action at the site of inflammation in the sinonasal passages. Lyra Therapeutics is located in the biotechnology region in Boston. For more information, please visit www.lyratx.com.
